151 related articles for article (PubMed ID: 35264144)
1. Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF.
Ebert K; Haffner I; Zwingenberger G; Keller S; Raimúndez E; Geffers R; Wirtz R; Barbaria E; Hollerieth V; Arnold R; Walch A; Hasenauer J; Maier D; Lordick F; Luber B
BMC Cancer; 2022 Mar; 22(1):254. PubMed ID: 35264144
[TBL] [Abstract][Full Text] [Related]
2. Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
Ebert K; Zwingenberger G; Barbaria E; Keller S; Heck C; Arnold R; Hollerieth V; Mattes J; Geffers R; Raimúndez E; Hasenauer J; Luber B
BMC Cancer; 2020 Oct; 20(1):1039. PubMed ID: 33115415
[TBL] [Abstract][Full Text] [Related]
3. Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.
Keller S; Zwingenberger G; Ebert K; Hasenauer J; Wasmuth J; Maier D; Haffner I; Schierle K; Weirich G; Luber B
Mol Oncol; 2018 Apr; 12(4):441-462. PubMed ID: 29325228
[TBL] [Abstract][Full Text] [Related]
4. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.
Kneissl J; Hartmann A; Pfarr N; Erlmeier F; Lorber T; Keller S; Zwingenberger G; Weichert W; Luber B
J Cancer Res Clin Oncol; 2017 Apr; 143(4):573-600. PubMed ID: 27933395
[TBL] [Abstract][Full Text] [Related]
5. MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells.
Ebert K; Mattes J; Kunzke T; Zwingenberger G; Luber B
PLoS One; 2019; 14(9):e0223225. PubMed ID: 31557260
[TBL] [Abstract][Full Text] [Related]
6.
Sanchez-Vega F; Hechtman JF; Castel P; Ku GY; Tuvy Y; Won H; Fong CJ; Bouvier N; Nanjangud GJ; Soong J; Vakiani E; Schattner M; Kelsen DP; Lefkowitz RA; Brown K; Lacouture ME; Capanu M; Mattar M; Qeriqi B; Cecchi F; Tian Y; Hembrough T; Nagy RJ; Lanman RB; Larson SM; Pandit-Taskar N; Schöder H; Iacobuzio-Donahue CA; Ilson DH; Weber WA; Berger MF; de Stanchina E; Taylor BS; Lewis JS; Solit DB; Carrasquillo JA; Scaltriti M; Schultz N; Janjigian YY
Cancer Discov; 2019 Feb; 9(2):199-209. PubMed ID: 30463996
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Afatinib and Lapatinib Against
Nakata S; Fujita M; Nakanishi H
Anticancer Res; 2019 Nov; 39(11):5927-5932. PubMed ID: 31704817
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
Yoshioka T; Shien K; Takeda T; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Soh J; Fujiwara T; Toyooka S
Cancer Sci; 2019 Aug; 110(8):2549-2557. PubMed ID: 31162771
[TBL] [Abstract][Full Text] [Related]
9. Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.
Kneissl J; Keller S; Lorber T; Heindl S; Keller G; Drexler I; Hapfelmeier A; Höfler H; Luber B
Int J Oncol; 2012 Aug; 41(2):733-44. PubMed ID: 22614881
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.
Yoshioka T; Shien K; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Asano H; Soh J; Tsukuda K; Nagasaka T; Fujiwara T; Toyooka S
Cancer Sci; 2018 Apr; 109(4):1166-1176. PubMed ID: 29465762
[TBL] [Abstract][Full Text] [Related]
11. Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.
Heindl S; Eggenstein E; Keller S; Kneissl J; Keller G; Mutze K; Rauser S; Gasteiger G; Drexler I; Hapfelmeier A; Höfler H; Luber B
J Cancer Res Clin Oncol; 2012 May; 138(5):843-58. PubMed ID: 22290393
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract][Full Text] [Related]
13. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
Sampera A; Sánchez-Martín FJ; Arpí O; Visa L; Iglesias M; Menéndez S; Gaye É; Dalmases A; Clavé S; Gelabert-Baldrich M; Poulsen TT; Kragh M; Bellosillo B; Albanell J; Rovira A; Montagut C
Mol Cancer Ther; 2019 Nov; 18(11):2135-2145. PubMed ID: 31484705
[TBL] [Abstract][Full Text] [Related]
14. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
Janjigian YY; Viola-Villegas N; Holland JP; Divilov V; Carlin SD; Gomes-DaGama EM; Chiosis G; Carbonetti G; de Stanchina E; Lewis JS
J Nucl Med; 2013 Jun; 54(6):936-43. PubMed ID: 23578997
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ; Farrelly AM; Cremona M; Carr A; Morgan C; Workman J; Armstrong P; McAuley J; Madden S; Fay J; Sheehan KM; Kay EW; Holohan C; Elamin Y; Rafee S; Morris PG; Breathnach O; Grogan L; Hennessy BT; Toomey S
J Transl Med; 2021 May; 19(1):184. PubMed ID: 33933113
[TBL] [Abstract][Full Text] [Related]
16. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
[TBL] [Abstract][Full Text] [Related]
17. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
18. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.
Arienti C; Zanoni M; Pignatta S; Del Rio A; Carloni S; Tebaldi M; Tedaldi G; Tesei A
Oncotarget; 2016 Apr; 7(14):18424-39. PubMed ID: 26919099
[TBL] [Abstract][Full Text] [Related]
20. In vitro antiproliferative effect of trastuzumab (Herceptin(®)) combined with cetuximab (Erbitux(®)) in a model of human non-small cell lung cancer expressing EGFR and HER2.
Privitera G; Luca T; Musso N; Vancheri C; Crimi N; Barresi V; Condorelli D; Castorina S
Clin Exp Med; 2016 May; 16(2):161-8. PubMed ID: 25716471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
